Vogenx, Inc.

Vogenx, Inc. filed its Form 10-Q for the period ending September 30, 2026. The company reported a significant increase in net loss to $4.91 million for the third quarter of 2026, compared to $284,407 in the same period of 2025. This was driven by a substantial rise in operating expenses, particularly in research and development, which increased from $124,813 to $1.08 million year-over-year. The company also highlighted the completion of its Initial Public Offering (IPO) in August 2026, which provided approximately $84.4 million in net proceeds, significantly bolstering its cash position to $82.1 million as of September 30, 2026.

Vogenx, Inc. filed a Second Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws in connection with its initial public offering. The Amended and Restated Charter authorizes 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock, while eliminating previous preferred stock series. The Amended and Restated Bylaws establish procedures for stockholder meetings and director nominations, conforming to the new charter.

Vogenx, Inc. has filed an S-1/A registration statement for its initial public offering, proposing to offer 6,250,000 shares of common stock at an expected price range of $11.00 to $13.00 per share. The company, a clinical-stage biopharmaceutical firm, aims to list its common stock on the Nasdaq Capital Market under the symbol "VOGX." Net proceeds, estimated at $67.8 million, will fund the continued development of its lead product candidate, mizagliflozin, for conditions like post-bariatric hypoglycemia and gastroparesis, and for general corporate purposes.